| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0003-4266(06)72569-0 |
| P698 | PubMed publication ID | 16639364 |
| P2093 | author name string | L C Hofbauer | |
| P2860 | cites work | Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone | Q39946634 |
| The effect of a single dose of osteoprotegerin in postmenopausal women | Q43520860 | ||
| A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases | Q44291815 | ||
| A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women | Q46133598 | ||
| Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord | Q73766127 | ||
| Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment | Q77337113 | ||
| Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma | Q77337118 | ||
| Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 | ||
| Osteoprotegerin: a novel secreted protein involved in the regulation of bone density | Q24313918 | ||
| RANK is essential for osteoclast and lymph node development | Q24598872 | ||
| Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand | Q24653311 | ||
| Bone resorption by osteoclasts | Q28145169 | ||
| OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis | Q28589430 | ||
| Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand | Q29619331 | ||
| Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression | Q33944735 | ||
| Role of RANK ligand in mediating increased bone resorption in early postmenopausal women | Q34912769 | ||
| RANK ligand and osteoprotegerin in myeloma bone disease. | Q34992857 | ||
| Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection | Q35008871 | ||
| Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. | Q35848843 | ||
| Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment | Q36232629 | ||
| Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis | Q36368706 | ||
| P433 | issue | 2 | |
| P921 | main subject | pathophysiology | Q1135939 |
| P304 | page(s) | 139-141 | |
| P577 | publication date | 2006-04-01 | |
| P1433 | published in | Annales d'Endocrinologie | Q15753551 |
| P1476 | title | Pathophysiology of RANK ligand (RANKL) and osteoprotegerin (OPG) | |
| P478 | volume | 67 |
| Q36171870 | Baseline serum RANKL levels may serve to predict remission in rheumatoid arthritis patients treated with TNF antagonists |
| Q40719297 | Increased calcification in osteoprotegerin-deficient smooth muscle cells: Dependence on receptor activator of NF-κB ligand and interleukin 6. |
| Q35886675 | No evidence of circulating autoantibodies against osteoprotegerin in patients with celiac disease |
| Q37059853 | Osteoporosis in celiac disease and in endocrine and reproductive disorders |
| Q37344527 | Role of RANKL-RANK/osteoprotegerin pathway in cardiovascular and bone disease associated with HIV infection |
| Q80463776 | [Bone metabolism: molecular mechanisms] |
| Q87840407 | [Inflammation and bone metabolism] |
| Q80149611 | [New pathophysological relevant metabolic pathways in osteoporosis. Future innovative therapies?] |
| Q90155672 | [Rheumatism and bone metabolism] |
Search more.